Dual progestin therapy for fertility-sparing treatment of grade 2 endometrial adenocarcinoma

A M Newtson; J B Pakish; A M Nick; S N Westin

doi:10.1016/j.gore.2017.08.001

Dual progestin therapy for fertility-sparing treatment of grade 2 endometrial adenocarcinoma

Gynecol Oncol Rep. 2017 Aug 8:21:117-118. doi: 10.1016/j.gore.2017.08.001. eCollection 2017 Aug.

Authors

A M Newtson¹, J B Pakish², A M Nick², S N Westin²

Affiliations

¹ University of Iowa Hospitals and Clinics, Department of Obstetrics and Gynecology, United States.
² The University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology and Reproductive Medicine, United States.

Abstract

•A case of grade 2 endometrial adenocarcinoma in a young woman desiring fertility-sparing treatment•Successful conservative management of refractory endometrial adenocarcinoma with dual progestin therapy•A brief review of conservative management in endometrial adenocarcinoma.

Publication types

Case Reports

Grants and funding

P50 CA098258/CA/NCI NIH HHS/United States